Cargando…

Metastatic Melanoma Epidural Tumour Regression Following Percutaneous Radiofrequency Ablation

Percutaneous radiofrequency ablation of spinal metastases is an emerging treatment for patients with painful metastatic spine disease. It is typically performed for patients who have not responded to conventional treatments or who have contraindications to radiotherapy. Destruction of the posterior...

Descripción completa

Detalles Bibliográficos
Autores principales: Papanikitas, Joseph, Fairhead, Rory, Chekroud, Ameen, Chung, Siok Li, McKean, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282353/
https://www.ncbi.nlm.nih.gov/pubmed/32528775
http://dx.doi.org/10.7759/cureus.8039
_version_ 1783544118114254848
author Papanikitas, Joseph
Fairhead, Rory
Chekroud, Ameen
Chung, Siok Li
McKean, David
author_facet Papanikitas, Joseph
Fairhead, Rory
Chekroud, Ameen
Chung, Siok Li
McKean, David
author_sort Papanikitas, Joseph
collection PubMed
description Percutaneous radiofrequency ablation of spinal metastases is an emerging treatment for patients with painful metastatic spine disease. It is typically performed for patients who have not responded to conventional treatments or who have contraindications to radiotherapy. Destruction of the posterior wall of the vertebral body and epidural disease may be considered relative contraindications for radiofrequency ablation. This is due to the difficulty in achieving satisfactory ablation balanced against the risk of neural injury. We describe a case of metastatic melanoma with an expansile lytic metastasis and epidural tumour extension at the L4 vertebral body level resulting in severe central canal stenosis. This was successfully treated with percutaneous radiofrequency ablation and vertebral augmentation. The patient reported significant pain relief post-procedure and follow-up MRI at two months demonstrated local tumour regression, epidural disease resolution and improved spinal canal dimensions. To the best of our knowledge, this is the first report of epidural disease resolution from metastatic melanoma following radiofrequency ablation and emphasises the potential benefits of ablation therapy even in the presence of canal stenosis and epidural metastatic disease.
format Online
Article
Text
id pubmed-7282353
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-72823532020-06-10 Metastatic Melanoma Epidural Tumour Regression Following Percutaneous Radiofrequency Ablation Papanikitas, Joseph Fairhead, Rory Chekroud, Ameen Chung, Siok Li McKean, David Cureus Pain Management Percutaneous radiofrequency ablation of spinal metastases is an emerging treatment for patients with painful metastatic spine disease. It is typically performed for patients who have not responded to conventional treatments or who have contraindications to radiotherapy. Destruction of the posterior wall of the vertebral body and epidural disease may be considered relative contraindications for radiofrequency ablation. This is due to the difficulty in achieving satisfactory ablation balanced against the risk of neural injury. We describe a case of metastatic melanoma with an expansile lytic metastasis and epidural tumour extension at the L4 vertebral body level resulting in severe central canal stenosis. This was successfully treated with percutaneous radiofrequency ablation and vertebral augmentation. The patient reported significant pain relief post-procedure and follow-up MRI at two months demonstrated local tumour regression, epidural disease resolution and improved spinal canal dimensions. To the best of our knowledge, this is the first report of epidural disease resolution from metastatic melanoma following radiofrequency ablation and emphasises the potential benefits of ablation therapy even in the presence of canal stenosis and epidural metastatic disease. Cureus 2020-05-09 /pmc/articles/PMC7282353/ /pubmed/32528775 http://dx.doi.org/10.7759/cureus.8039 Text en Copyright © 2020, Papanikitas et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pain Management
Papanikitas, Joseph
Fairhead, Rory
Chekroud, Ameen
Chung, Siok Li
McKean, David
Metastatic Melanoma Epidural Tumour Regression Following Percutaneous Radiofrequency Ablation
title Metastatic Melanoma Epidural Tumour Regression Following Percutaneous Radiofrequency Ablation
title_full Metastatic Melanoma Epidural Tumour Regression Following Percutaneous Radiofrequency Ablation
title_fullStr Metastatic Melanoma Epidural Tumour Regression Following Percutaneous Radiofrequency Ablation
title_full_unstemmed Metastatic Melanoma Epidural Tumour Regression Following Percutaneous Radiofrequency Ablation
title_short Metastatic Melanoma Epidural Tumour Regression Following Percutaneous Radiofrequency Ablation
title_sort metastatic melanoma epidural tumour regression following percutaneous radiofrequency ablation
topic Pain Management
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282353/
https://www.ncbi.nlm.nih.gov/pubmed/32528775
http://dx.doi.org/10.7759/cureus.8039
work_keys_str_mv AT papanikitasjoseph metastaticmelanomaepiduraltumourregressionfollowingpercutaneousradiofrequencyablation
AT fairheadrory metastaticmelanomaepiduraltumourregressionfollowingpercutaneousradiofrequencyablation
AT chekroudameen metastaticmelanomaepiduraltumourregressionfollowingpercutaneousradiofrequencyablation
AT chungsiokli metastaticmelanomaepiduraltumourregressionfollowingpercutaneousradiofrequencyablation
AT mckeandavid metastaticmelanomaepiduraltumourregressionfollowingpercutaneousradiofrequencyablation